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Abstract  1 
Background: Cell-based regenerative medicine therapies are now frequently tested in 2 
clinical trials. In many conditions, cell therapies are administered systemically, but there is 3 
little understanding of their fate, and adverse events are often under-reported. Currently, it 4 
is only possible to assess safety and fate of cell therapies in preclinical studies, specifically by 5 
monitoring animals longitudinally using multimodal imaging approaches. Here, using a suite 6 
of in vivo imaging modalities to explore the fate of a range of human and murine cells, we 7 
investigate how route of administration, cell type and host immune status affect the fate of 8 
administered cells. Methods: We applied a unique imaging platform combining 9 
bioluminescence, optoacoustic and magnetic resonance imaging modalities to assess the 10 
safety of different human and murine cell types by following their biodistribution and 11 
persistence in mice following administration into the venous or arterial system.  Results: 12 
Longitudinal imaging analyses (i) suggested that the intra-arterial route may be more 13 
hazardous than intravenous administration for certain cell types; (ii) revealed that the 14 
potential of a mouse mesenchymal stem/stromal cell (MSC) line to form tumours, depended 15 
on administration route and mouse strain; and (iii) indicated that clinically tested human 16 
umbilical cord (hUC)-derived MSCs can transiently and unexpectedly proliferate when 17 
administered intravenously to mice. Conclusions: In order to perform an adequate safety 18 
assessment of potential cell-based therapies, a thorough understanding of cell 19 
biodistribution and fate post administration is required. The non-invasive imaging platform 20 
used here can expose not only the general organ distribution of these therapies, but also a 21 
detailed view of their presence within different organs and, importantly, tumourigenic 22 
potential. Our observation that the hUC-MSCs but not the human bone marrow (hBM)-23 
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derived MSCs persisted for a period in some animals, suggests that therapies with these cells 1 
should proceed with caution. 2 
 3 
Keywords: cell therapies, mesenchymal stem/stromal cells, safety, preclinical models, cell 4 
tracking, multi-modal imaging. 5 
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Background 1 
In recent years, biomedical and translational research has focussed on exploring the 2 
potential of regenerative medicine therapies (RMTs) to treat a vast number of diseases[1]. A 3 
primary safety concern of RMTs, especially if based on stem cells, is their potential to form 4 
tumours, due to their proliferative and multi-potential differentiation characteristics[2]. 5 
Mesenchymal stem/stromal cells (MSCs) isolated from bone marrow, adipose tissue or 6 
umbilical cord are being tested in clinical trials for a range of conditions, but in many cases, 7 
preclinical safety data are not available, and the authors fail to report whether the cells 8 
cause any adverse effects. Bone marrow-derived MSCs have been used for many years and 9 
appear safe[3], but a review of adipose-derived MSCs concluded that while adverse events 10 
are rare, they nevertheless do occur, and are likely to be related to underlying health 11 
conditions of the patients or administration route[4]. Human umbilical cord-derived (hUC)-12 
MSCs have only recently been introduced in clinical trials, with more than 50% of these 13 
initiated within the last 3 years (a summary of registered trials in presented in Additional File 14 
1). hUC-MSCs are less immunogenic than other types of MSCs, which contributes to their 15 
attraction as clinical RMTs. However, because of their low immunogenicity in combination 16 
with higher proliferative behaviour, these cells may also pose a greater potential risk[5], yet 17 
until now, their safety profile has not been robustly assessed. The importance of preclinical 18 
safety testing is highlighted by a recent report where a tumour developed in a patient’s 19 
spinal cord following intrathecal administration of stem cells[6].  20 
 21 
Assessing the safety of cell therapies by tracking their distribution and fate over time after 22 
administration can be achieved in preclinical models. Many animal studies use lipophilic 23 
membrane dyes, such as PKH26 or CM-Dil, to label the cells, which requires culling of 24 
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animals at various time points and histological analysis[7-11]. The key flaws of this approach 1 
are (1) the detection of false positive cells because lipophilic dyes have the potential to 2 
transfer to host cells[12]; (2) very large animal numbers, infringing on the principles of the 3 
3Rs (Replacement, Reduction, Refinement); and (3) the failure to longitudinally monitor the 4 
cell fate in each individual animal over time. By contrast, non-invasive imaging technologies 5 
have opened up exciting new possibilities for preclinical assessment of the safety of cell 6 
therapies by allowing longitudinal in vivo cell tracking to monitor cell biodistribution and 7 
persistence. Preclinical imaging technologies for cell tracking, some of which have clinical 8 
relevance, include magnetic resonance imaging (MRI) to detect cells labelled with 9 
superparamagnetic iron oxide nanoparticles (SPIONs), multispectral optoacoustic 10 
tomography (MSOT) to detect cells labelled with gold nanorods (GNRs) or near-infrared red 11 
fluorescent protein[13-17], and bioluminescence imaging (BLI) for the detection of cells 12 
expressing the genetic reporter, firefly luciferase[18-20]. Genetic reporters are particularly 13 
advantageous because signals are only generated from living cells, thus allowing the 14 
monitoring of cell proliferation and tumour growth, and avoiding problems based on 15 
nanoparticle dissociation from cells, which can lead to false positive signals. However, the 16 
spatial resolution of BLI is poor, making it difficult to precisely locate the cells[18]. By 17 
contrast, both preclinical MSOT and MRI have much higher spatial resolution (150 µm and 18 
50 µm, respectively), providing details of the inter- and intra-organ distribution of 19 
administered cells. Moreover, as MRI is routinely used in the clinic, it provides a bridge for 20 
preclinical and clinical studies.  21 
An advanced approach to longitudinal in vivo cell tracking is the use of multi-modal imaging 22 
strategies that combine cell labels and reporters, including dual-labelling with both the 23 
luciferase reporter gene for BLI, and either gold nanorods (GNRs) for photoacoustic 24 
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imaging[21-24], or superparamagnetic iron oxide nanoparticles (SPIONs) for MRI[25-28]. Such 1 
multi-modal imaging approaches benefit from the sensitivity of the luciferase-based signal 2 
conferred by living cells, in combination with the high resolution of MRI and photoacoustic 3 
imaging systems to detect the nanoparticles inside organs, allowing a comprehensive 4 
longitudinal analysis of cell fate and safety risks. 5 
 6 
The most common way to administer cells systemically in small animals is via the intravenous 7 
(IV) route through the tail vein [29], delivering cells directly to the lungs where they are 8 
sequestered as a consequence of the pulmonary first-pass effect[30-35]. Previous reports 9 
have suggested that IV administered cells labelled with lipophilic dyes bypass the lungs, but 10 
this is likely due to false positive staining. For example, in renal regenerative studies, PKH26 11 
dye-labelled IV administered cells have been reported to engraft in injured kidneys and 12 
replace damaged renal cells [9-11, 36], but a more recent study using this lipophilic dye in 13 
combination with GFP expression shows that while the dye can sometimes be detected in the 14 
kidneys, the cells remain trapped in the lungs[32]. These recent findings are corroborated by 15 
in vivo cell tracking studies which show that after IV injection, transplanted cells 16 
predominantly accumulate in the lungs[19, 33, 34], fail to integrate or differentiate into tissue-17 
specific cell types and disappear within 7 days [19, 20, 37].  18 
Although the IV route is also frequently used in clinical trials, administration via the arterial 19 
circulation is not uncommon. For instance, clinical trials testing the potential of cell therapies 20 
to treat myocardial infarction administer cells into the coronary arteries or left cardiac 21 
ventricle[24, 38], while in patients with peripheral artery disease or stroke, intra-arterial 22 
injection via the femoral or carotid artery, respectively, is frequently employed[39]. Intra-23 
arterial administration will also lead to systemic distribution to other organs, including the 24 
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brain, and cells passing through the blood-brain barrier could pose an important safety 1 
concern. However, a detailed analysis of cell fate after intra-arterial cell administration has 2 
so far not been reported [4].  3 
Here, we have implemented a multi-modal imaging approach comprising BLI, MSOT and 4 
MRI, to assess biodistribution and fate of different cell types following venous and arterial 5 
administration in healthy mice. Some of these cell types are currently being used in clinical 6 
trials, including hUC-MSCs (Additional File 1), hBM-MSCs[40], kidney-derived cells[41] and 7 
macrophages[42]. We show that our multi-modal imaging approach allows us to determine 8 
the immediate distribution of the cells with respect to the route of administration, and to 9 
assess the long-term fate of mouse and human MSCs, and their propensity to form tumours.  10 
Our findings demonstrate that the multi-modal imaging platform allowing longitudinal cell 11 
tracking is an important tool to identify safety concerns of cells used in clinical trials. 12 
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Methods 1 
Animals 2 
Mice (Charles River, UK) were housed in individually ventilated cages under a 12 hour 3 
light/dark cycle, with ad libitum access to standard food and water. All animal experiments 4 
were performed under a licence granted under the UK Animals (Scientific Procedures) Act 5 
1986 and were approved by the University of Liverpool ethics committee. Experiments are 6 
reported in line with the ARRIVE guidelines. Tumour formation was closely monitored and 7 
the tumour burden was not allowed to exceed the recommended size[43]. 8 
 9 
Cell Preparation  10 
Mouse kidney-derived stem cells (mKSCs)[44], the D1 mouse MSC (mMSC) line (D1 ORL UVA 11 
[D1](ATCC® CRL-12424™)), primary human umbilical cord-derived MSCs (hUC-MSCs; 12 
collected from consenting donors and produced identically to those already being used in 13 
clinical trials by NHS Blood and Transplant (NHSBT)), primary human bone marrow-derived 14 
MSCs (hBM-MSCs; Lonza PT-2501), human kidney cells (hKCs; kidneys deemed unsuitable for 15 
transplantation via UK NHSBT[32]) and RAW264.7 macrophages (European Collection of 16 
Authenticated Cell Cultures 91062702) were cultured at 37°C under a humidified 17 
atmosphere with 5% CO2 (culture media are described in Additional File 2). Primary human 18 
cells were used up to passage 8, whereas mouse lines were cultured up to passage 25.  19 
For detection by BLI, cells were transduced with a lentiviral vector encoding either firefly 20 
luciferase (Luc) or a bicistronic construct of Luc and ZsGreen, all under control of the 21 
constitutive promoter EF1a. The vector plasmids were a gift from Bryan Welm (Addgene 22 
plasmids # 21375 and 39196) and the production of viral particles and cell transduction was 23 
carried out as previously described[45, 46]. The mKSCs were infected with a multiplicity of 24 
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infection (MOI) of 10, whereas all other cells were infected with an MOI of 5. At least 90% of 1 
the cell populations expressed the vector after transduction, except for macrophages, which 2 
did not tolerate polybrene and thus displayed a reduced infection efficiency. Cell sorting 3 
based on ZsGreen fluorescence obtained a macrophage population that was 100% positive 4 
for the luciferase construct.  Cells for karyotyping were treated with colcemid (0.1 µg/mL) 5 
followed by a hypotonic treatment and fixation in Carnoy’s fixative. Chromosome analyses 6 
were carried out by cytogenetics specialists (CellGS, Cambridge, UK). 7 
Average cell diameter was estimated by measuring the volume of a cell pellet in a packed 8 
cell volume (PCV) tube according to the manufacturer’s instructions (Techno Plastic 9 
Products, Switzerland). The cell diameter was calculated using the formula: 10 
 11 
∅𝑐𝑒𝑙𝑙 = 2 × ∛
3𝑉 𝑐⁄
4𝜋
 12 
where V corresponds to the pellet volume, and c to the number of cells in the pellet.  13 
For MR tracking, cells were labelled with diethylaminoethyl-dextran coated SPIONs 14 
synthesised in house as previously described[25, 26]. SPIONs were added to the culture 15 
medium at a concentration of 25 µg[Fe]/mL 24h prior to the experiment, after which cells 16 
were washed to remove excess particles and harvested for administration as described 17 
below. This resulted in an iron content of ~ 6 pg[Fe]/cell. 18 
GNRs were synthesised using a protocol first reported by El-Sayed’s group[47] and coated 19 
with silica as described by Comenge et al.[23]. Macrophages were labelled for 24h with 20 
GNRs at a final concentration of 10 pM before harvesting for cell injection. Neither of the 21 
labelling approaches (SPIONs/GNRs) caused any reduction in cell viability.  22 
 23 
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Cell administration 1 
Cells were trypsinised, pelleted, resuspended in ice-cold phosphate buffered saline (PBS) and 2 
kept on ice until injection. 100µl cell suspension was administered to mice via intravenous 3 
(IV) or ultrasound-guided intracardiac (IC) injection. A description and comments on this 4 
method of administration is provided in Additional File 3. Tolerance of dosing of cells was 5 
adjusted in separate experiments. 6 
 7 
Bioluminescence imaging 8 
Short-term study: ZsGreen+/Luc+ mMSCs, mKSCs, hKCs, macrophages or Luc+ hUC-MSCs 9 
were administered IV or IC to BALB/c mice. Long-term study: ZsGreen+/Luc+ mMSCs or Luc+ 10 
hUC-MSCs were administered by IV or IC to BALB/c (severe combined immunodeficient) 11 
SCID mice (see Table 1 for route, cell dose and number of animals in each experiment). The 12 
in vivo biodistribution of cells was monitored by BLI immediately after cell administration, 13 
and at multiple time points up to 30 days. Mice were administered 150 mg/kg body weight 14 
luciferin (Promega, UK) subcutaneously, and imaged 15 min later in a bioluminescence 15 
imager (IVIS Spectrum, Perkin Elmer, UK). Imaging data were normalised to the acquisition 16 
conditions and expressed as radiance (photons/second/cm2/steradian (p/s/cm2/sr)), and the 17 
colour scale was adjusted according to the strength of signal detected. Because IV injections 18 
into the tail can lead to a small fraction of cells remaining in or around the injection site, 19 
causing strong signal intensities, the tails of animals that received cells via this route were 20 
covered prior to data acquisition. At the respective study end points, mice were culled and 21 
organs with any visibly identifiable tumours imaged ex vivo by BLI. Kidneys were cut 22 
coronally for ex vivo imaging, and all other organs were imaged whole. Bioluminescence 23 
signals of whole live mice or individual organs ex vivo were quantified by drawing regions of 24 
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interest (ROIs) from which the total flux (photons/second) was obtained. The relative signal 1 
intensity from each organ was calculated as a percentage of the signal intensity from all 2 
organs. For ex vivo kidney imaging, the ROI was drawn around all four kidney halves and a 3 
single value for total bioluminescence signal was recorded. 4 
 5 
Multispectral Optoacoustic Tomography (MSOT) 6 
MSOT was carried out using the inVision 256-TF MSOT imaging system (iThera Medical, 7 
Munich). Images were recorded at the following wavelengths: every 10 nm from 660 nm and 8 
760nm, and every 20 nm from 780 nm and 900 nm, at a rate of 10 frames per second and 9 
averaging 10 consecutive frames. All mice were allowed to equilibrate in the imaging system 10 
for 15 minutes prior to recording data. For monitoring of the biodistribution of macrophages 11 
after IV administration, a 15 mm section of the abdomen to include the liver, kidneys and 12 
spleen of the mice was imaged repeatedly for a total of 4.5 hours; 30 minutes into the 13 
imaging the mice received the macrophages via a tail vein catheter. For the IC imaging a 15 14 
mm section of the abdomen was imaged once, followed by an ultrasound (Prospect 2.0, S-15 
Sharp, Taipei city) guided injection of 107 macrophages into the left ventricle of the heart. 16 
Mice were then returned to the photoacoustic imaging system for imaging as previously 17 
described. Data was reconstructed and multispectral processing was performed to resolve 18 
signals in the liver, kidney and spleen for GNRs. Regions of interest were drawn around the 19 
liver, right kidney and spleen (an example is shown in Additional File 4) to generate mean 20 
pixel intensity data.  21 
 22 
MR imaging 23 
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ZsGreen+/Luc+/SPION+ mMSCs (106) were administered to BALB/c mice IV (n = 2) or IC (n = 2 1 
for short-term analysis; n = 5 for longitudinal tracking). The biodistribution of cells in the 2 
brain and kidney was imaged with a Bruker Avance III spectrometer interfaced to a 9.4T 3 
magnet system (Bruker Biospec 90/20 USR) using a Fast Low-Angle Shot (FLASH) T2* 4 
weighted sequence at baseline and up to 2 days post administration. T2* relaxation times 5 
were obtained from a T2* map generated with a multi-gradient echo sequence by drawing 6 
ROIs around the cortex of the kidney (an example is shown in Additional File 5) or a region of 7 
the liver. At least one animal was culled at each time point for histological analyses, and 8 
brains and kidneys were fixed with 4% formaldehyde and imaged at a higher resolution post 9 
mortem (all MRI acquisition parameters are described in the Additional File 6). Tumours 10 
were imaged with a T2 weighted fast spin echo sequence. 11 
 12 
Histopathological analysis 13 
Perfusion fixed frozen brain and kidney sections were stained for the endothelial cell marker 14 
isolectin B4 (IB4, L2140, Sigma Aldrich, UK) as described previously[48]. The presence of 15 
ZsGreen+ mMSCs within brain and glomerular capillaries was imaged by confocal microscopy 16 
(LSM 800 Airyscan, Zeiss). Frozen kidney sections (7µm) were stained for the presence of 17 
iron (Iron Stain Kit, Sigma, UK) according to manufacturer’s instructions to detect SPIONs, 18 
and consecutive sections were counterstained with DAPI. Prussian blue stained cells and 19 
ZsGreen-positive mMSCs were imaged by bright field and epifluorescence microscopy. 20 
Tumours were fixed in 4% paraformaldehyde at 4°C for 24h, washed in PBS and processed 21 
through an ethanol and xylene series before embedding in paraffin. Five µm tissue sections 22 
were stained for haematoxylin and eosin (H&E) by standard methods and morphologically 23 
assessed. 24 
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 1 
Fluorescence activated cell sorting (FACS) 2 
Bone marrow was extracted as previously described[49]. In short, femurs and tibias were 3 
collected in PBS containing penicillin/streptomycin, the bone marrow was flushed out with 4 
PBS, centrifuged (400 g, 5 mins) and then resuspended in fresh PBS before analysis by flow 5 
cytometry for ZsGreen expression. 6 
 7 
Statistical Analyses 8 
Statistical analyses were performed using Minitab 17 statistical software. A one-way analysis 9 
of variance (ANOVA) was used to compare multiple groups. When an ANOVA resulted in a 10 
statistically significant result (p < 0.05), a Tukey pairwise comparison was performed in order 11 
to determine which groups were significantly different. The Tukey pairwise comparison 12 
assigned each group at least one letter, and groups that did not share a letter were 13 
significantly different from one another.  14 
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Results 1 
Whole body biodistribution of different cell types following intravenous (IV) and intracardiac 2 
(IC) administration 3 
Bioluminescence imaging showed that IV delivery of ZsGreen+/Luc+ mouse MSCs (mMSCs), 4 
mouse kidney-derived stem cells (mKSCs) and human kidney cells (hKCs) resulted in signals 5 
exclusively in the lungs, while signals from IV-administered macrophages were also located 6 
more posteriorly (Fig. 1a). This was expected because macrophages are known to traverse 7 
the lungs and populate other organs, such as the liver and spleen. In contrast, intra-arterial 8 
delivery via the left heart ventricle (from now on referred to as intra-cardiac (IC)) resulted in 9 
a whole-body distribution of all cell types (Fig. 1a). 10 
Organ-specific ex vivo imaging within 1h of IV administration of mKSCs confirmed that the 11 
signal was limited to the lungs (Fig. 1b, d). In contrast, after IC administration, 12 
bioluminescent signals were detected in the brain, heart, lungs, kidney, spleen, and liver (Fig. 13 
1b, d). IV-administered macrophages were found predominantly within the lungs by ex vivo 14 
imaging (Fig. 1c), but weaker signals were also detected in the spleen and liver, kidneys and 15 
brain, confirming the in vivo signal distribution. Ex vivo analysis of macrophages after IC 16 
injection showed signals in most organs that were imaged (Fig. 1c, e).  17 
To monitor the temporal dynamics of macrophage migration, cells were labelled with GNRs, 18 
injected IV, and monitored continuously for 4.5h using MSOT. Signal intensity began to 19 
increase immediately in both the liver and spleen until around 90 min when it started to 20 
plateau (Fig. 1f), but remained close to basal levels in the kidney, consistent with BLI ex vivo 21 
analysis (Fig. 1e, f). However, when GNR-labelled macrophages were administered IC, 22 
increases in signal intensity in the kidney were comparable to those in the liver and spleen 23 
4h post-administration (quantification is shown in Additional File 4c).  24 
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  1 
Cell distribution within organs using high-resolution magnetic resonance imaging 2 
Since the spatial resolution of BLI is poor, we used MRI to evaluate the intra-organ 3 
biodistribution of ZsGreen+/Luc+/SPION+ mMSCs after IV or IC administration, focussing 4 
particularly on the brain and kidneys. Following IC injection, T2* weighted imaging revealed 5 
hypointense areas distributed homogenously throughout the brain (Fig. 2a), and localised in 6 
the cortex of the kidneys (Fig. 2b). However, hypointense contrast was not detected in the 7 
brain or kidneys of IV-injected mice, confirming that IV administration does not deliver 8 
mMSCs to either of these organs (Fig. 2a, b). Post mortem MR imaging of extracted organs 9 
performed at higher resolution confirmed the hypointense contrast throughout the brain 10 
and in the renal cortex of IC-injected mice (Fig. 2a, b).  11 
Histological analysis of ZsGreen expression by fluorescence microscopy in combination with 12 
Prussian Blue staining of SPIONs showed that labelled cells were located in the renal 13 
glomeruli (Fig. 2c). ZsGreen and Prussian Blue signals corresponded to the same spatial 14 
location, indicating that hypointense contrast in vivo was unlikely to result from false-15 
positive detection of SPIONs (e.g. released from dead cells). To determine whether IC-16 
administered cells had undergone extravasation, we performed confocal imaging of IB4-17 
stained blood vessels in organs within 5 hours after cell administration. This demonstrated 18 
that ZsGreen+ mMSCs were physically trapped in the lumen of microcapillaries (Fig. 2d), 19 
suggesting that the cells did not cross the blood brain barrier or the glomerular filtration 20 
barrier.  21 
 22 
Short-term fate of IC-injected cells  23 
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To determine how long the cells persisted in major organs we injected 106 1 
ZsGreen+/Luc+/SPION+ mMSCs into the left cardiac ventricle of BALB/c mice and tracked their 2 
fate in vivo by MRI and BLI, and post mortem by MRI and fluorescence microscopy (Fig. 3a). 3 
On the day of injection (day 0), whole-body distribution of IC-administered mMSCs by 4 
bioluminescence signals was observed, while in the kidneys, MRI revealed hypointense 5 
contrast specifically in the cortex. By day 1, the bioluminescence signal intensity decreased, 6 
suggesting cell death. Correspondingly, fewer hypointense areas were observed in the renal 7 
cortex by MRI, supporting the disappearance of SPION-labelled cells. By day 2, 8 
bioluminescence was no longer detectable in the abdominal region, nor was any significant 9 
hypointense SPION contrast observed in the kidneys with MRI. This was confirmed by high-10 
resolution MRI of organs ex vivo, showing a decrease in contrast in the renal cortex over 11 
time, and a decrease in the frequency of ZsGreen+ mMSCs in kidney glomeruli by 12 
fluorescence microscopy (Fig. 3a). Changes in the T2* relaxation time in the renal cortex 13 
indicated the relative number of SPION-labelled cells present at each time point. T2* was 14 
significantly lower on the day of cell administration (Fig. 3b) than at baseline but then 15 
increased towards baseline levels at day 1 and day 2. Because the liver is the major organ for 16 
clearance of blood-transported particulates, we quantified the hepatic T2* relaxation time, 17 
which revealed a subtle but significant decrease from baseline through to day 2 (Fig. 3c). 18 
These results suggest that following cell death, SPIONs accumulate predominantly in the 19 
liver and are not retained by the kidneys. 20 
 21 
Effect of administration route on the long-term biodistribution and fate of mMSCs  22 
To assess the effect of administration route on the long-term fate of cells, ZsGreen+/Luc+ 23 
mMSCs were administered to BALB/c SCID mice by IC or IV routes, and biodistribution 24 
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monitored by BLI at multiple time points over 28 days. While both IC and IV injection 1 
resulted in the typical immediate biodistribution patterns (Fig. 1a), by day 4 following IV and 2 
IC administration, the bioluminescence signal was undetectable, indicating loss of cells via 3 
cell death (Fig. 4a). Continued imaging over time showed that bioluminescence signals began 4 
to increase again in animals after IC injection from around day 14, but not in animals after IV 5 
injection. The increase in signal was particularly prominent in the hindquarters of all five IC-6 
injected mice at day 14, and increased further until day 30 (Fig. 4a, Additional File 7a). 7 
Detailed analysis of animals after IV administration of mMSCs revealed that bioluminescence 8 
signals in the lungs of one mouse increased over time (Additional File 7b). Overall, whole-9 
body bioluminescence intensity initially decreased following both IC and IV administration, 10 
and subsequently increased rapidly in the IC-injected mice (Fig. 4b-d).  11 
 12 
Osteosarcoma formation after IC administration of mMSCs  13 
Multiple abnormal growths were present in IC-injected BALB/c SCID mice, predominantly in 14 
skeletal muscle surrounding the femurs, but also in muscle near the hips, ribs, and spine (Fig. 15 
5a, f), suggesting tumours had formed. Tumour sites corresponded to foci of intense BLI 16 
signals which could also be identified using T2 weighted MR imaging (Fig. 4e). Furthermore, 17 
T2 weighted MR imaging allowed us to detect an abnormal mass in the lungs of one (out of 18 
three) IV-injected mouse that displayed an intense bioluminescence signal (Fig. 4e, 19 
Additional File 7b). Although cells of the mMSC line have been suggested to home to the 20 
bone marrow[50], flow cytometry analysis showed the bone marrow was negative for 21 
ZsGreen+ cells (Additional File 8). Histologically, tumours were characterised by atypical solid 22 
proliferation of spindle cells associated with multifocal formation of pale amorphous 23 
eosinophilic material (osteoid). The tumours were therefore classified as osteosarcomas (Fig. 24 
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5h, j, k). Frozen sections of the tumour tissue exhibited specific ZsGreen fluorescence (Fig. 1 
5i), further confirming the neoplasms originated from mMSCs.  2 
Chromosomal analysis of the mMSCs revealed a grossly abnormal karyotype of between 65 3 
and 67 chromosomes, with multiplications and unidentified chromosomes (shown in 4 
Additional File 9a).  5 
 6 
Formation of mMSC-derived tumours in different mouse strains  7 
To determine whether tumours developed because the BALB/c SCID mice were 8 
immunocompromised, we investigated the long-term fate of the mMSCs following IC 9 
administration in three different immunocompetent mouse strains: BALB/c (same genetic 10 
background as mMSCs), FVB (unrelated inbred strain), and MF1 (unrelated outbred strain). 11 
The biodistribution immediately after injection was similar between the strains, but at day 12 
28, only the BALB/c mice displayed bioluminescence signals as high as those in the BALB/c 13 
SCID mice (Fig. 5a-d). Moreover, the timing and location of tumour formation was consistent 14 
in all immunocompetent and immunocompromised BALB/c mice. In the FVB and MF1 15 
strains, mMSC foci tended to form in similar locations as with the BALB/c mice, but 16 
bioluminescence signals were weaker. Although signal intensity gradually increased in FVB 17 
mice from d7 to d28, in MF1 outbred mice, signals increased initially up to d21, but then 18 
started to decrease as the mMSC foci began to regress (Fig. 5e).  19 
 20 
Long-term biodistribution of hUC-MSCs in BALB/c SCID mice  21 
Since mMSCs gave rise to tumours in immuno-compromised and –competent mice, 22 
predominantly after systemic arterial injection, we aimed to determine whether clinically 23 
relevant MSCs could carry a similar health risk. We focussed on well-studied hBM-MSCs as 24 
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well as hUC-MSCs, as the latter are currently being used in an increasing number of clinical 1 
trials (Additional File 1). The chromosomal analysis for both hBM-MSCs and hUC-MSCs 2 
revealed a normal karyotype (Additional File 9b,c). We analysed the long-term fate of hUC-3 
MSCs via the IC and IV route at two different cell doses, 1 x 106 and 5 x 105, showing 4 
consistent results (Table 1). 5 
When following the fate of both of these cell types after IV or IC administration in BALB/c 6 
SCID mice, we found that in most cases, BLI signals became weaker within a few days of 7 
administration, and remained undetectable for the duration of the study (hBM-MSCs: 4 8 
weeks; hUC-MSCs: 8 weeks) (Fig. 6a). Ex vivo analysis of the organs on the day of injection 9 
suggested that similar to the other cell types, a whole-body distribution is obtained when 10 
cells are injected into the arterial system, and cells are mostly trapped in the lungs when the 11 
venous route is used. However, in the case of hUC-MSCs, BLI signal was sometimes observed 12 
in the heart (Figure 6b). When imaging the same organs without the lungs, and with an 13 
increased detection sensitivity, the signal in the heart became more obvious, while very 14 
weak signals could also be observed in other organs (Additional File 10).  Interestingly, long-15 
term imaging of mice that had received hUC-MSCs via the IV route revealed that in a small 16 
number of animals (~25%) foci had developed in locations beyond the lungs (Fig. 6c, red 17 
arrows), although in all cases these regressed within the time course of the experiment.   18 
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Discussion 1 
 2 
Here, we have employed a novel platform approach of non-invasive preclinical imaging 3 
encompassing BLI, MRI and MSOT to assess the biodistribution and persistence of a range of 4 
mouse and human cell types following IV and IC administration in healthy mice. These cells 5 
included mouse MSCs, kidney stem cells and macrophages, as well as human kidney-derived 6 
cells and two types of human MSCs, which are already being tested as cell therapies in 7 
clinical trials.  8 
As expected, immediate analysis after IV administration revealed that apart from 9 
macrophages, all other cell types were mostly sequestered in the lungs, although small 10 
numbers of hUC-MSCs could be detected in other organs following ex vivo analysis. After IC 11 
administration, all cell types showed a widespread distribution. However, irrespective of the 12 
administration route, analysis using BLI and MRI determined that cells disappeared from 13 
major organs within 24-48 hours, which based on the loss of BLI signals, was likely due to cell 14 
death.  15 
A number of preclinical cell therapy studies have reported that IV administered cells reached 16 
the relevant injured organs, where they incorporated and contributed to the regeneration of 17 
healthy and functional tissue [7, 9, 10, 51, 52]. It had been postulated that the mechanisms 18 
by which the cells, especially MSCs, reached the injured organs was based on the release of 19 
trophic factors which attracted the cells to the relevant injury site [33, 53]. An important 20 
problem with these studies was that cells had mostly been labelled with membrane dyes (DiI 21 
or PKH26) which were detected in the injured organ; however, as we have recently 22 
demonstrated, membrane dyes easily dissociate from the cells, leading to misinterpretation 23 
of the presence of administered cells [32]. Therefore, more sophisticated approaches to cell 24 
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labelling and tracking have been established, including bioluminescence imaging of 1 
luciferase-transduced cells [17, 54]. This method is specific to living cells because the signal is 2 
dependent on production of the enzyme firefly luciferase. Here, we have demonstrated, as 3 
others before [32, 34, 55, 56], that IV administered cells are generally sequestered in the 4 
first vascular bed they encounter, which is the lung microvasculature, where they die and 5 
then disappear within 2 days. 6 
Since a number of preclinical studies have shown that administered cells fail to incorporate 7 
and directly contribute to the regeneration of the damaged tissue in injured organs despite 8 
leading to beneficial effects in organ function and histology, it is highly relevant to 9 
understand the mechanisms by which efficacy is provided. Increasing evidence points 10 
towards paracrine factors that are released by the dying cells, with beneficial effects on 11 
organ function. This probably occurs through activation of immunomodulatory pathways 12 
that initiate regeneration or, possibly, also via other protective functions [31, 32, 56]. It is 13 
currently not understood whether these effects are based on direct and short-term 14 
interactions between cytokines and immune cells, stimulating an anti-inflammatory switch, 15 
or if epigenetic changes are involved, which could lead to long-term effects.  16 
We explored an alternative systemic administration route by injecting cells directly into the 17 
left ventricle, and demonstrated that this route delivered the cells directly to organs, instead 18 
of sequestration in the lungs. Our observation that cells are cleared very quickly from the 19 
major organs following IC administration indicates that the arterial route poses no significant 20 
advantage for cell therapy administration. However, it is possible that small numbers of cells 21 
reaching the organs after IC administration may still be able to locally exert beneficial roles 22 
through paracrine effects before they are cleared. Therefore, further research is required to 23 
explore the local role of IC delivered cells. 24 
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Using our platform of imaging techniques, we were able to provide some mechanistic insight 1 
into the fate of macrophages after administration, which have been demonstrated to confer 2 
beneficial effects in organ injury models [57, 58]. Macrophages have been previously shown 3 
to home to the liver and spleen after passage through the lungs [59]. However, the dynamics 4 
of this homing process had not been described. Using multi-modal BLI and MSOT [24], we 5 
could monitor macrophage accumulation in the liver and spleen for 4.5h continuously at 6 
high temporal resolution. We found that labelled macrophages immediately started to 7 
accumulate in liver and spleen, particularly in the first ~90 min, which indicated that some of 8 
the macrophages instantly passed through the pulmonary circulation. 9 
While BLI has the advantage of highly sensitive body-wide detection of luciferase-expressing 10 
cells, its spatial resolution is poor, which prevents organ-focussed imaging. To visualise cells 11 
within major organs such as kidney and brain, and monitor their fate over time, we 12 
implemented a bimodal approach comprising BLI and MRI, taking advantage of the high 13 
spatial resolution of MRI in addition to the high sensitivity of BLI and the fact that luciferase 14 
activity is dependent on cell viability[15-18].  15 
It should be noted that labelling of cells for preclinical imaging approaches raises a number 16 
of questions regarding the interpretation of the findings. While lentiviral labelling is typically 17 
a process that results in stable expression of the reporter protein of interest, and as in our 18 
case of luciferase, with high sensitivity, exposure to lentiviral particles and the resulting 19 
expression of exogenous proteins could possibly affect the immunogenicity of the cells [60], 20 
which may have downstream effects on recognition by the endogenous immune system. 21 
Because we have used SCID mice for most of our studies, especially those with human MSCs, 22 
possible immunogenicity will unlikely have affected the results. In addition, luciferase signal 23 
will disappear when cells are phagocytosed, but may remain if cells undergo cell fusion. 24 
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Therefore, loss of BLI signal is a clear sign of loss of cells through cell death, while continued 1 
presence of signal could also indicate a change in cell phenotype by cell fusion. By contrast, 2 
SPION or GNR labels may still be detectable after cells have been phagocytosed or fused, 3 
potentially leading to misinterpretation. To our knowledge, SPIONs and GNRs have not 4 
shown to modify the immunogenicity of labelled cells. To avoid false signals, dual or triple 5 
labelling of cells using a combination of genetic direct reporters and nanoparticles could 6 
address this problem. We have recently shown that a combination of labels can indeed 7 
provide detailed information on the dynamics of cell fate, as GNR-labelled mouse MSCs 8 
which also expressed a near infrared reporter protein, disappeared within 2 days after IC 9 
injection from the various organs in which they could be detected initially, and instead GNRs 10 
accumulated in the liver. By contrast, the reporter protein visualised the increase in cells in 11 
tumours forming in sites similar to the ones reported here [24]. A genetic reporter is highly 12 
suitable for the detection of multiplying cells, for example in tumours, where the GNRs or 13 
other nanoparticles would get diluted out with increasing numbers of cell divisions.  14 
Our detailed analysis of the biodistribution of mMSCs after IC injection using in vivo, and 15 
subsequently ex vivo MR imaging techniques revealed that SPION-labelled cells were 16 
scattered throughout the brain, while in the kidneys, they were restricted to the cortical 17 
regions. Ex vivo histological staining and fluorescence microscopy demonstrated that cells in 18 
the kidneys were found only within the glomeruli, bounded by endothelial cells within the 19 
microvasculature, where they appeared to be trapped. Similarly, cells in the brain were only 20 
localised within the microvasculature, indicating that they lack the capacity to pass through 21 
the blood brain barrier. These results demonstrate that the mMSCs cannot extravasate into 22 
the brain and kidneys. 23 
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During long-term cell tracking of the BALB/c-derived mMSCs, we observed tumour formation 1 
in skeletal muscle following IC administration to a similar degree in immune-competent 2 
BALB/c mice as in BALB/c SCIDs. mMSCs also gave rise to tumours in an unrelated inbred 3 
strain, albeit at a slower rate, while in an unrelated outbred strain, small foci of mMSCs 4 
expanded at early time points and later regressed. Taken together, these data suggest that 5 
the adaptive immune system might not be able to recognise tumours derived from 6 
syngeneic MSCs, and that the genetic background of the host appears to have an effect on 7 
the propensity of MSCs to form tumours. This could be a concern for human trials using 8 
autologous MSCs where the ability of the cells to form tumours may not be detected by the 9 
recipient’s immune system. Furthermore, the results suggest that the risk of tumour 10 
formation might depend on undefined genetic factors that would vary from patient to 11 
patient. However, it is important to note that karyotype testing of the mMSC line used here 12 
revealed a range of chromosomal abnormalities, which could contribute to their propensity 13 
to form tumours. In a recent study, a clonal mouse MSC line derived from the 14 
immortomouse was found to persist for up to 33 weeks after intra-arterial injection, in the 15 
distal femur of SCID mice in which the respective leg had been injured by irradiation [55]. 16 
However, while the BLI signal of firefly luciferase expressed by the mMSCs increased over 17 
time, tumours were not reported. 18 
Our observation that mMSCs distributed to most organs following IC injection, but tumours 19 
were predominantly localised in the skeletal muscles and not within the organs they 20 
originally appeared in, raises the question of how tumour formation is regulated in different 21 
organs and tissues. Our data indicate that the cells had a ’survival advantage‘ in muscular 22 
tissue, but not in the brain and the kidneys, from which they failed to extravasate. We 23 
hypothesise that following IC administration, a small number of MSCs were able to 24 
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extravasate from the capillaries in the skeletal muscle where they started to proliferate. The 1 
mechanisms that regulate the ability of the mMSCs to extravasate and form tumours in the 2 
skeletal muscle but not in other organs are not known, and further analysis is required to 3 
determine the molecular and cellular factors controlling this process.  4 
Our results also show that the cells failed to home to and populate the bone marrow, which 5 
is surprising given the cells had been originally isolated from the bone marrow[61]. The D1 6 
mMSC line used here has not previously been reported to generate invasive tumours, since 7 
subcutaneously injected cells provided no evidence of metastasizing, even if they 8 
proliferated at the injection site[23, 62]. Our observation that the mMSCs did not form 9 
tumours outside the lung following IV administration is therefore consistent with this 10 
finding.  However, the formation of osteosarcomas in the skeletal muscle after IC 11 
administration of mMSCs in this study is in line with the previously described formation of 12 
osteosarcomas after adoptive transfer of primary MSCs, particularly for cells expanded in 13 
vitro, and is a major safety concern in therapies using MSCs[63, 64].  14 
Since these observations suggested that arterial administration of MSC-based cell therapies 15 
could have important safety implications, we followed the fate of MSC derived from the 16 
bone marrow or the umbilical cord of healthy human donors. We confirmed that neither of 17 
these cells presented any major chromosomal aberrations, even after transduction with the 18 
luciferase reporter. While in most animals the cells became undetectable within a few days 19 
after IV administration, in a few mice the hUC-MSCs persisted longer, albeit transiently, in 20 
other body regions where their presence was not expected. Of note, a transient persistence 21 
of hUC-MSCs was not observed after IC administration, nor for hBM-MSCs using IV or IC 22 
administration routes. We suggest that this unusual behaviour is not linked to cell size, 23 
because the hUC-MSCs are not smaller than mKSCs or mMSCs, but could possibly be due to 24 
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their surface proteins, allowing some of the cells to escape the lungs[33, 65]. The 1 
observation that hUC-MSC foci appeared in a small number of mice, grew in size, but later 2 
disappeared, was difficult to explain, especially given that the mice were SCIDs and thus 3 
lacked an adaptive immune system. It is possible that the cells eventually elicited a 4 
xenogeneic response involving macrophages and natural killer cells[66], after initially 5 
suppressing the native immune system, which is one of their central properties[67, 68]. 6 
Alternatively, the hUC-MSCs may have expanded in the animal but then become senescent 7 
and died, irrespective of the host’s ability to mount an immune response. Thus, after an 8-8 
week period of cell tracking, we could not observe any tumour growth by in vivo or ex vivo 9 
BLI in all SCID mice to which hUC-MSCs had been administered by either IV or IC injection. 10 
However, the observation that the IV-injected hUC-MSCs persisted for a time period in 25% 11 
of the animals indicates that these cells carry greater safety risks and suggests that clinical 12 
therapies with these cells should proceed with caution with an appropriate risk management 13 
plan. Further preclinical studies are needed to determine the mechanisms by which hUC-14 
MSCs were able to persist as well as eventually disappear in order to better define the 15 
potential for tumourigenicity. The imaging platform presented here provides the necessary 16 
biotechnology for preclinical evaluation of the potential tumourigenicity of cell products 17 
used for cell transplantation, for which there is presently no internationally recognised 18 
guideline.  19 
 20 
Conclusions 21 
Cell-based therapies are currently being considered for a range of diseases, some of which 22 
are already undergoing clinical trials. A robust biodistribution and safety assessment is 23 
essential for understanding cell fate and ensuring patient welfare. Here, we demonstrate a 24 
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safety assessment platform that can expose not only the general organ distribution of 1 
potential cell therapies, but also a detailed view of their presence within different organs. 2 
Importantly, by using this imaging platform, we show that the route of administration affects 3 
the range of organs that the cells can reach, and, particularly, their propensity to form 4 
tumours.  Our assessment suggests that cells are short-lived irrespective of whether they are 5 
administered via the venous or arterial circulation, and that the risk of cell persistence or 6 
tumour formation is dependent on the cell type, route of administration and immune status 7 
of the host. Crucially, we show that clinically used, human umbilical cord-derived 8 
mesenchymal stem/stromal cells form transient unexpected self-limited proliferations in 9 
various anatomical regions when administrated intravenously. The implications of this 10 
observation require further investigations and should be taken into account when clinical 11 
trials are considered. 12 
 13 
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Figure Legends 16 
 17 
Figure 1. Biodistribution of different cells following intravenous or intracardiac 18 
administration. (a) BLI immediately after administration, showing that cells were always 19 
confined within the lungs after intravenous (IV) administration, but distributed throughout 20 
the body after intracardiac (IC) administration; an exception were the macrophages which 21 
showed also a more posterior signal after IV administration. The diameter of each cell as 22 
estimated by the PCV is shown next to the images. Ex vivo bioluminescence imaging of 23 
organs within 1h of administration of (b) mKSCs or (c) macrophages confirmed the in vivo 24 
cell biodistribution. Organs are indicated as kidneys (k), spleen (s), liver (li), lungs (lu), heart 25 
(h) or brain (b) and the colour scale applies to both administration routes. Quantification of 26 
the bioluminescence signal intensity of organs ex vivo post (d) mKSC or (e) macrophage 27 
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administration. Values represent the mean signal intensity measured in each organ and 1 
normalised to the total flux from all organs (n = 3 each group). Error bars represent standard 2 
error. (f) Mean pixel intensity of GNR-labelled macrophages measured via multispectral 3 
optoacoustic tomography for a period of 5 hours post IV administration, displaying the 4 
kinetics of their accumulation in the spleen and liver.  Arrow indicates the time point at 5 
which the cells were administered. 6 
 7 
Figure 2. MRI and immunofluorescence images of mMSCs in the brains and kidneys. In vivo 8 
and post-mortem T2*-weighted images of the (a) brains and (b) kidneys of mice pre- and 9 
post-administration of SPION-labelled mMSCs via the IV or IC route. (c) Epifluorescence of 10 
Zsgreen (green) and nuclei (blue) of a single kidney glomerulus (top) and the corresponding 11 
Prussian Blue image (bottom) demonstrating that cells and SPIONs co-localised to the same 12 
spatial location. Scale bars correspond to 10 µm. (d) Overlay of confocal microscopy images 13 
of Isolectin-IB 4 staining (red), ZsGreen (green) and nuclei (blue). Tissue sections were 14 
obtained from the brain (left) or kidney (right) of mice culled within 5 hours after having 15 
received cells IC.  16 
 17 
Figure 3. Short-term fate of mMSCs imaged in vivo and post-mortem.  (a) BLI, MRI (in vivo, 18 
post-mortem) and fluorescence microscopy images of the kidneys immediately (on day 0, 19 
within 5 hours), or on day 1 or day 2 after IC administration of SPION-labelled mMSCs. 20 
Fluorescence images were obtained from tissue sections where green fluorescence 21 
corresponds to ZsGreen expression and blue fluorescence to DAPI staining. Arrowheads 22 
indicate individual glomeruli. Scale bar corresponds to 100 µm.  T2* relaxation time of (b) 23 
kidney cortices or (c) liver before (baseline) and up to 2 days after cell administration. The 24 
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T2* relaxation time in the cortex of the kidney was significantly lower on the day of cell 1 
administration (day 0, mean = 7.98 ms +/- SE = 0.29) than at baseline (14.56 +/- 0.32 ms; 2 
One-way ANOVA, p < 0.001). The T2* relaxation time then increased towards baseline levels 3 
at day 1 (12.57 +/- 0.50 ms) and day 2 (13.19 +/- 0.23 ms), and by day 2 the difference 4 
compared with baseline levels was no longer statistically significant. In the livers, T2* 5 
relaxation time revealed a subtle but significant decrease in relaxation time from baseline to 6 
day 2 (baseline, 7.19 +/- 0.29 ms; day 0, 5.48 +/- 0.38 ms; day 1, 5.10 +/- 0.16 ms; day 2, 5.02 7 
+/- 0.94 ms; One-way ANOVA, p = 0.006). Time points that do not share the same letters are 8 
significantly different from one another, p < 0.05 (Tukey's post hoc test). 9 
 10 
Figure 4. Impact of administration route on long-term tumour formation. (a) 11 
Representative BLI of SCID mice administered with mMSC via the IC or IV route. BLI scale 12 
corresponds to levels between 1.0x105-1.0x106 p/s/cm2/sr. Quantification of the 13 
bioluminescence signal from each individual mouse that received mMSCs (b) IC (n=5) or (c) 14 
IV (n=3) up to day 17. Signal corresponds to a region of interest drawn around the whole 15 
body of the mouse.  (d) Mean whole body quantification of the bioluminescence signal up to 16 
day 30. Error bars represent SE. (e) T2-weighted MRI of tumours in animals that received 17 
mMSCs via IC or IV as imaged 30 days post administration. Arrows indicate individual 18 
tumours, usually in the skeletal muscle apart from the IV route, where a tumour was found 19 
close to the lungs.  20 
 21 
Figure 5. Tumour-formation potential in different mouse strains. Representative BLI of 22 
longitudinal tumour monitoring in four strains of mouse following IC administration of 23 
mMSCs. (a) immunocompromised BALB/c SCID, (b) Immunocompetent BALB/c (c), FVB or (d) 24 
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MF1 mice. BALB/c mice showed very similar tumour formation potential to BALB/c SCID 1 
mice, with respect to timing, size and location of tumour development. After 21 days, the 2 
strong signal originating from the tumours required a colour scale two orders of magnitude 3 
greater than that at 0h to accurately display the tumour location. FVB and MF1 mice 4 
displayed weaker BLI foci at day 28, and not all animals displayed the same tumour 5 
distribution. Balb/c SCID data in (a) has been partially reproduced from Fig. 4a to facilitate 6 
comparison between strains. (e) Mean whole body quantification of the bioluminescence 7 
signal up to day 30. Error bars represent SE. (f) Photograph of the hindquarters of a Balb/c 8 
mouse after removal of the skin. Multiple tumour foci are indicated with arrows, 9 
demonstrating their presence in the skeletal muscle close to the femurs, hips, and spine. (g) 10 
BLI of tumours harvested 30 days post-administration of mMSCs confirming that tumours 11 
originated from the administered cells and not host tissue. (h-k) Histological examination of 12 
tumour tissue. (h) H&E staining and corresponding (i) epifluorescence imaging of the 13 
ZsGreen reporter. Differences in cell composition between the tumour (**) and normal 14 
tissue (*) are denoted. Scale bars represent 100 µm. (j, k) Higher magnification of tumour 15 
tissue showing cancer cells arranged in densely cellular monomorphic areas. Scale bars 16 
correspond to 50 µm and arrow indicates mitotic figures, one of which is shown in the inset. 17 
(k) Corresponds to an area where the tumour is moderately cellular with production of 18 
unmineralised osteoid (black arrowhead) and partially mineralised matrix (red arrowhead). 19 
 20 
Figure 6. Long-term monitoring of human MSCs in Balb/c mice. (a) Representative BLI of 21 
mice administered with 5x105 hBM-MSC or hUC-MSC via the IC or IV route. The signal was 22 
progressively lost shortly after administration, with no evidence of malignant growth. (b) Ex 23 
vivo bioluminescence imaging of organs within 5h of administration of the cells. Organs are 24 
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indicated as kidneys (k), spleen (s), liver (li), lungs (lu), heart (h) or brain (b). In some 1 
occasions signal foci were seen in the heart of mice that received hUC-MSC IV (red arrow). 2 
(c) BLI images from mice that displayed hUC-MSC signal that persisted beyond day 7 (ventral 3 
orientation, lower scale). In all cases, the signals had disappeared by day 21 and had not 4 
returned by the end of the experiment.  5 
 6 
 7 
Tables 8 
 9 
Table 1. Experimental details of studies, mouse strains, cell types, route of administration, 10 
dose and number of animals studied  11 
Study Mouse strain Cell Type Route Dose 
Number of 
animals 
BLI short-term 
biodistribution 
(and MSOT for 
RAW 
macrophages) 
BALB/c mMSC IV and IC 1.0 x106 
Minimum n = 3 
for each cell 
type and 
administration 
route 
BALB/c mKSC IV and IC 1.0 x106 
BALB/c hUC-MSC IV and IC 1.0 x106 
BALB/c hBM-MSC IV and IC 5.0 x105 
BALB/c hKC IV and IC 0.3 x105 
BALB/c macrophages IV and IC 1.0 x107 
BLI long-term 
biodistribution 
BALB/c SCID mMSC IV 1.0 x106 n = 3 
BALB/c SCID mMSC IC 1.0 x106 n = 5 
BALB/c  mMSC IC 1.0 x106 n = 4 
FVB mMSC IC 1.0 x106 n = 4 
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MF1 mMSC IC 1.0 x106 n = 4 
BALB/c SCID hUC-MSC IV 1.0 x106 n = 13 
BALB/c SCID hUC-MSC IC 1.0 x106 n = 3 
BALB/c SCID hUC-MSC IV 5.0 x105 n = 6 
BALB/c SCID hUC-MSC IC 5.0 x105 n = 14 
BALB/c SCID hBM-MSC IV 5.0 x105 n = 6 
BALB/c SCID hBM-MSC IC 5.0 x105 n = 6 
MRI cell 
tracking 
BALB/c mMSC IV 1.0 x106 n = 2 
BALB/c mMSC IC 1.0 x106 n = 7 
 1 
Cell numbers for IC administration had to be individually optimised for each cell type used 2 
since mice responded severely to higher numbers of some of the cell types after injection 3 
into the left ventricle. Administered cell numbers caused no health problems after IV 4 
injection in any of the cell types used.  5 
 6 
 7 
Additional File Legends 8 
 9 
Additional File 1 (pdf). Summary of registered clinical studies involving umbilical cord-10 
derived MSCs. 11 
 12 
Additional File 2 (pdf). Culture media used for growing cells. 13 
 14 
Additional File 3 (pdf). Detailed method of ultrasound guided intracardiac injection of cells. 15 
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 1 
Additional File 4 (pdf). MSOT images of GNR-labelled macrophages in different organs. 2 
Snapshot images of the abdomen of mice, showing the (a) liver, delineated with red lines 3 
and (b) kidney, delineated with a yellow line or spleen, delineated with a green line. Images 4 
correspond to baseline imaging (pre-administration) and 4h post IV administration of GNR-5 
labelled RAW macrophages. GNR-labelling generates MSOT contrast, seen as an increase in 6 
pixel brightness for areas corresponding to liver and spleen. Kinetic imaging over a period of 7 
4h was used to generate data shown in Fig. 1f.  (c) Quantification of the MSOT mean pixel 8 
intensity in the liver, spleen or kidneys 4h post administration of GNR-labelled RAW 9 
macrophages IV or IC. Data is displayed as fold changes in pixel intensity in respect to 10 
baseline measurements. 11 
 12 
Additional File 5 (pdf). Placement of a region of interest (ROI) for the calculation of 13 
relaxation time in the kidney’s cortex. (a) In vivo T2*-weighted image of a single kidney post 14 
administration of SPION-labelled mMSCs, (b) placement of an ROI (yellow line) covering the 15 
cortex of the kidney where cell/SPION contrast is observed and (c) the changes in signal 16 
intensity as a function of echo time, with the solid line displaying the exponential fit of the 17 
data, from where the relaxation time is derived. Relaxation times were calculated with 18 
Paravision 6.0.1. 19 
 20 
Additional File 6 (pdf). MRI sequences and acquisition parameters. All in vivo data was 21 
acquired with a 4-channel surface coil designed for the mouse brain or abdomen. Post 22 
mortem data was obtained with a 27 mm volume coil. 23 
 24 
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Additional File 7 (pdf). mMSC distribution between day 14 and 30. (a) From day 24 1 
onwards for IC-injected mice, it was necessary to increase the scale by two orders of 2 
magnitude (BLI scale 1.0 x107 – 1.0 x108 p/s/cm2/sr, orange frame) compared to that in Fig. 3 
4 to enable visualisation of the very strong signals resulting from rapidly proliferating 4 
mMSCs. (b) Using the original scale (see Fig. 4: 1.0 x105 – 1.0 x106 p/s/cm2/sr), signals could 5 
be detected by day 24 in one (out of 3) IV-injected mice. (c,e) Representative in vivo and 6 
corresponding (d,f) ex vivo organ images at day 30. (d) Small spots of bioluminescence signal 7 
could be detected in some of the organs of IC-injected BALB/c SCID mice (arrows), but the 8 
scale had to be lowered to 1.0 x104 – 1.0 x105 p/s/cm2/sr (blue frame) in order to be able to 9 
display these weak signals. (e) Two out of three IV-administered BALB/c SCID mice did not 10 
show any signals at day 30 in vivo using the standard scale (green frame), however, 11 
corresponding (f) organ imaging showed small foci of bioluminescence signals in the lungs 12 
(arrows). 13 
 14 
Additional File 8 (pdf). Fluorescence Activated Cell Sorting (FACS) analysis of bone marrow 15 
extracts.  Green fluorescence analysis of cells harvested from the femurs and tibias of (a) a 16 
control mouse that received no cells (b) a mouse that received mMSCs IC display no 17 
evidence of ZsGreen+ cells in the bone marrow. 18 
 19 
Additional File 9 (pdf). Chromosome analysis of the (a) mMSCs, (b) hBM-MSCs and (c) hUC-20 
MSCs. Whereas mMSCs displayed a grossly abnormal karyotype, the human cells displayed a 21 
normal female karyotype. 22 
 23 
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Additional File 10 (pdf). Ex vivo imaging of organs immediately after administration of 106 1 
hUC-MSC. (a) Intracardiac administration always results in BLI signal originating from organs 2 
in addition to the lungs. Intravenous administration, on the other hand, leads to cells lodging 3 
predominantly in the lungs. For hUC-MSCs, however, a weak signal was seen in heart, which 4 
was particularly noticeable when the lungs were removed from the imaging field. BLI scale: 5 
all organs 1.0x105 – 1.0 x107 p/s/cm2/sr, lungs removed: 1.0x104 – 4.0 x105 p/s/cm2/sr. (b-c) 6 
Relative bioluminescence intensity in each organ as measured ex vivo post (b) IC or (c) IV 7 
administration. The signal intensity of mKSCs as shown in Fig. 1d is displayed as a reference. 8 
Note that following IV administration, the sum of the signal in organs other than the lungs is 9 
generally less than 2% of the total. A break has been inserted in the y-axis to facilitate the 10 
visualisation of the data. 11 
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